ArticleClinical and translational science2022

A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.

Fabiany da Costa Gonçalves et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.